Key points from article :
Apollo Health Ventures has raised $180 million to fund early entrants in the burgeoning race to prolong human life.
“A paradigm shift from treating age-related diseases long after first symptoms have developed to targeting the root causes at earlier stages,” - Nils Regge, Apollo co-founder and partner.
First fund added four companies, including Aeovian Pharmaceuticals and Ochre Bio.
New round has brought Booster Therapeutics, Refoxy Pharma, Haya Therapeutics, Galilei Biosciences, and two others in stealth mode.
Looking to grow its portfolio to 10-15 companies over the next 3 years, according to partner Marianne Mertens.
Considering how a company’s technology might translate to other disease areas, or slow the progression of age-related diseases.
Mertens said, tackling the “root causes of aging,” from neurodegenerative disease to diabetes.
“We just see that there’s tremendous, tremendous new knowledge around the aging pathways,” - Mertens.
